Retrospective Cohort Study
Copyright ©The Author(s) 2019.
World J Clin Cases. Jun 6, 2019; 7(11): 1270-1281
Published online Jun 6, 2019. doi: 10.12998/wjcc.v7.i11.1270
Table 3 Crude and adjusted hazard ratios for end-stage renal disease
VariableCrude
Adjusted1
HR95%CIP valueHR95%CIP value
CKD patients
Uninfected1.00Reference1.00Reference
Treated0.310.13-0.770.0110.340.14-0.840.019
Untreated1.251.00-1.560.0461.281.03-1.600.029
Sex, men/women1.110.89-1.380.351.230.99-1.550.07
Age, per year1.011.00-1.010.150.990.98-0.990.006
Comorbidity, yes/no
Diabetes2.872.28-3.61< 0.0013.062.37-3.95< 0.001
Hypertension3.082.37-4.01< 0.0013.512.57-4.79< 0.001
Coronary heart disease1.281.02-1.590.0310.920.72-1.160.46
Hyperlipidemia1.291.04-1.600.0230.850.68-1.070.16
Cirrhosis0.620.46-0.830.0010.610.44-0.840.003
ACEI/ARB, yes/no1.380.65-2.920.400.960.46-2.040.92
Enrollee category
11.00Reference1.00Reference
20.680.21-2.14)0.500.560.17-1.800.33
31.260.97-1.640.081.240.95-1.630.11
41.471.09-1.990.0121.401.03-1.920.03
Number of medical visits1.001.00-1.010.361.000.99-1.000.41
Charlson comorbidity index score1.0100.98-1.040.460.930.89-0.980.008